Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS

Pharmacogenomics

Volumn 8, Issue 11, 2007, Pages 1511-1519

  Fargher, Emily A ^a,b   Eddy, Charlotte ^b   Newman, William ^b,c   Qasim, Faieza ^d   Tricker, Karen ^a,b   Elliott, Rachel A ^e   Payne, Katherine ^a,b  

^a Nowgen Centre   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Azathioprine; Education; Enzyme testing; Pharmacogenetics; Preferences; Qualitative research; Service delivery; Thiopurine methyltransferase; Training

Indexed keywords

AZATHIOPRINE;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; HUMAN; KIDNEY TRANSPLANTATION; KNOWLEDGE; MALE; MEDICAL EDUCATION; NATIONAL HEALTH SERVICE; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PHARMACOGENETICS; SEMI STRUCTURED INTERVIEW;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; DELIVERY OF HEALTH CARE; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHARMACOGENETICS; PROFESSIONAL-PATIENT RELATIONS; QUALITATIVE RESEARCH; QUALITY OF HEALTH CARE; QUESTIONNAIRES;

EID: 37349037641     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.11.1511     Document Type: Article

References (33)

1. Evans WE, Relling MV: Moving towards individualised medicine with pharmacogenetics. Nature 429, 464-468 (2004).
2. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann, Clin. Biochem. 41, 294-302 (2004).
3. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HBLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
4. Scordo MG, Spina E, Romeo P et al.: CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur. J. Clin. Pharmacol. 56, 679-683 (2000).
5. Maitalnd ML, Vasisht K, Ratain MJ: TPMT, UGTIA1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. 27(8), 432-437 (2006).
6. Holme SA, Duley JA, Sanderson J et al.: Erythrocyte thiopurine methyltransferase assessment prior to azathioprine use in the UK. QJM 95, 439-444 (2002).
7. Fargher EA, Tricker K, Newman W et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin. Pharm. Ther. 32, 187-195 (2007).
8. Anstey AV, Wakelin S, Reynolds NJ: British Association of Dermatologists Therapy, guidelines and audit subcommittee. Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151, 1123-1132 (2004).
9. Chakravarty K, McDonald H, Pubar T et al. on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group in association with the British Association of Dermatologists (BAD): BSR & BHPR guideline for disease-modifying anti-rheumatic drug therapy (DMARD) in consultation with the British Association of Dermatologists. Rheumatology (2006) DOI: 10.1093/rheumatology/ke1216a (Advance access).
10. Latif DA: Pharmacogenetics and pharmacogenomics instruction in schools of pharmacy in the USA: is it adequate? Pharmacogenomics 6(4), 317-319 (2005).
11. Gurwitz D, Lunshof JE, Dedoussis G et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical and health schools deans of education. Pharmacogenomics J. 5(4), 221-225 (2005).
12. Frueh FW, Gurwitz D: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5(5), 571-579 (2004).
13. Shah J: Criteria influencing the clinical uptake of pharmacogenomic strategies. Br. Med J. 328, 1482-1486 (2004).
14. Phillips KA, Veenstra DL, Oren E et al.: Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA 286, 2270-2279 (2001).
15. Department of Health: The New NHS: Modern, Dependable. HMSO, London, UK (1997).
16. Nuffield Council on Bioethics: Pharmacogenetics Ethical Issues: Report of Working Party. Nuffield Council on Bioethics, London, UK (2003).
17. Clemerson JP, Payne K, Bissell P, Anderson C: Pharmacogenetics, the next challenge for pharmacy? Pharm. World Sci. 28(3), 126-130 (2006).
18. Almarsdottir AB, Björnsdöttir I, Traulsen JM: A lay prescription for tailor-made drugs - focus group reflections on pharmacogenomics. Health Policy 71(2), 233-241 (2005).
19. Bevan JL, Lynch JA, Dubriwny TN et al.: Informed lay preferences for delivery of racially varied pharmacogenomics. Genet. Med. 5(5), 393-399 (2003).
20. Condit C, Bates B: How lay people to messages about genetics, health and race. Clin. Genet. 68(2), 97-105 (2005).
21. Rogausch A, Prause D, Schallenberg A, Brockmöller J, Himmel W: Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 7(1), 1-3 (2006).
22. Veenstra DL: Bringing genomics to the bedside: a cost-effective pharmacogenetic test? Pharmacogenetics 14, 333-334 (2004).
23. Glaser BG, Strauss AL: Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Sage, London, UK (1967).
24. Strauss A, Corbin J: Basics of Qualitative Research: Grounded neary Procedures and Techniques. Sage, London, UK (1990).
25. Lanie AD, Jayaratne TE, Sheldon JP: Exploring the public understanding of basic genetic concepts. J. Genet, Couns. 13(4), 305-321 (2004).
26. Bowling A: Research Methods in Health (Second Edition), Open Universtty Press, Maidenhead, UK (2004).
27. Bryman A, Burgess RG: Analysing Qualitative Data. Routtedge, London, UK (1994).
28. Green J: Commentary: grounded theory and the constant comparative method. Br. Med, J. 316(7137), 1064-1065 (1998).
29. Crabtree BJ, Miller WL: Using codes and code manuals. In: Doing Qualitative Research (Second Edition). Crabtree BF, Miller WL (Eds). Sage Publications, London, UK 163-177 (1999).
30. Payne K, Newman W., Fargher E, Tricker K, Bruce I, Other WER: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (2007) DOI: 10.1093/rheumatology/ke1427 (Epub ahead of print).
31. Hedgecoe A: At the point at which you can do something about it, then it becomes more relevant: informed consent in the pharmacogenetic clinic. Soc. Sci. Med. 61, 1201-1210 (2005).
32. Lunshof J: Teaching and practicing pharmacogenomics: a complex matter. Pharmacogenomics 7(2), 243-246 (2006)
33. Hedgecoe A: Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics 8(3), 267-270 (2007).